繁 简 About Us Company Profile Corporate Structure Milestones Core Business R&D and Production Base Zhuhai R&D and Production Base Kunming R&D and Production Base Global Sales Network Chinese Medicine Development Chinese Medicine R&D Chinese Medicinal Materials Decoction Slices Biomedical Technology and Products Tianda Products Pipeline Quality Healthcare Services Investor Relations Corporate Information Corporate Governance Announcements & Circulars Financial Statements Shares and Details Investor Calendar Investor Enquiries Email Alerts Notices (Replacement of Lost Share Certificates) Dissemination of Corporate Communications Sustainability Our Sustainable Development ESG Report Careers Wort At Tianda Recruitment Vacancies Internship Programmes Trainee Programmes Media Centre Press Releases Media Coverage Contact Us 2020 Select Year 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 03.08.2020 Tianda Pharmaceuticals Plans to Launch 100 TDMalls and Explores New Markets (Ming Pao) 30.07.2020 Tianda Pharmaceuticals (00455.HK): Capturing Market Opportunities, Striving to Become a Leader in Promoting Chinese Medicine Inheritance, Innovation and Development (Ta Kung Pao) 08.05.2020 Previously provided complimentary TCM herbs in Macau, Tianda Pharmaceuticals “Anti-Epidemic Formula 1” approved to sell in Australia (Macau Daily) 08.05.2020 Private Enterprise in China: Tianda Pharmaceuticals “Anti-Epidemic Formula 1” granules approved to sell in Australia (Multi-sources) 08.05.2020 Tianda Pharmaceuticals（00455）“Anti-Epidemic Formula 1” granules approved to sell in Australia (Multi-sources) 07.05.2020 Tianda Pharmaceuticals（00455）“Anti-Epidemic Formula 1” granules approved for entry into the Australian Register of Therapeutic Goods as a listed medicine (Sina Finance)
